CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL

Nima Zamiri,John W. Eikelboom,Paul A. Reilly,Michael D. Ezekowitz,Jonas Oldgren,Salim Yusuf,Stuart J. Connolly

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2016）

引用 1|浏览7

暂无评分

摘要

CHA2DS2-VASc and HAS-BLED scores are widely used for risk stratification to guide decision making in use of anticoagulation therapy in atrial fibrillation (AF). RE-LY trial compared efficacy of dabigatran vs. Warfarin in AF. We evaluated accuracy of CHA2DS2-VASc vs. HAS-BLED in predicting risk of

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要